



Tuberculosis among Diabetes Patients: A Review of Epidemiology, Pathophysiology, Clinical Manifestations, and Management

Muhammad Abid Munir¹, Sulaman Khan², Sana Rehman³, Dawood Ahmed², Abdul Jabbar²

¹Chongqing University, China

²The University of Haripur, Haripur Pakistan

³NIH-HRI Central Research Centre National Institute of Health Islamabad, Pakistan

ARTICLE INFO

Article Type: Review Article

Received on: June 30, 2024.

Revised on: August 31, 2024.

Accepted on: September 2, 2024.

Keywords: Clinical Management;
Diabetes Mellitus;
Epidemiology;
Pathophysiology;
Tuberculosis.

Corresponding author: Muhammad Abid Munir
mian.abid09@gmail.com

ABSTRACT

The intersection of tuberculosis (TB) and diabetes mellitus (DM) poses a significant global health challenge, with each condition exacerbating the other's clinical course and outcomes. This review explores the epidemiological burden, pathophysiological interactions, clinical manifestations, diagnostic challenges, and treatment strategies for managing TB in patients with diabetes. Understanding the bidirectional relationship between TB and diabetes is crucial for developing effective public health interventions and clinical management guidelines to mitigate the impact of these coexisting conditions. The risk factors contributing to the co-occurrence of TB and diabetes are multifaceted, involving both biological and socio-environmental components. Chronic hyperglycemia in diabetes leads to various immune dysfunctions, such as impaired cytokine production, reduced neutrophil activity, and altered macrophage function, all of which are critical components of the body's defense against TB infection. The clinical presentation of TB in diabetic patients can be atypical and often more severe compared to non-diabetic individuals. This atypical presentation may delay diagnosis and worsen outcomes. Addressing the dual burden of TB and diabetes requires integrated care models that bring together TB and diabetes services under a unified approach. Understanding of epidemiology, pathophysiology and clinical manifestation of TB, diabetes and co-infection are necessary to understand for disease control. The intersection of TB and diabetes represents a significant public health challenge that requires urgent attention and a coordinated response. The bidirectional relationship between these two diseases exacerbates their impact, leading to higher morbidity and mortality, especially in resource-limited settings. Effective management of TB-diabetes comorbidity requires an integrated approach.

Citation: Munir MA, Khan S, Rehman S, Ahmed D, Jabbar A. Tuberculosis among diabetes patients: a review of epidemiology, pathophysiology, clinical manifestations, and management. Chron Biomed Sci. 2024;1(3):26. Available from: <https://cbosciences.us/index.php/cbs/article/view/26>.

Introduction

Tuberculosis (TB) and diabetes mellitus (DM) are two chronic conditions with a profound impact on global health. TB is a leading infectious cause of morbidity and mortality, particularly in low- and middle-income countries, while DM is a growing non-communicable disease with increasing prevalence worldwide, driven by

lifestyle changes, urbanization, and aging populations. The convergence of these two diseases has garnered significant attention due to their synergistic effects on patient outcomes, public health, and healthcare systems [1]. Diabetes is associated with an increased risk of developing active TB, with diabetic patients having approximately three times the risk compared to non-diabetic individuals [2]. Conversely, TB can worsen

glycemic control, complicating diabetes management. The coexistence of these conditions presents unique challenges in diagnosis, treatment, and overall patient management, necessitating integrated approaches to care [3]. This review aims to provide a comprehensive analysis of the epidemiological trends, pathophysiological mechanisms, clinical presentations, diagnostic considerations, treatment protocols, and management strategies for TB among diabetes patients. By highlighting the complexities of this intersection, we aim to inform clinicians, researchers, and policymakers about the critical need for coordinated efforts in addressing this dual burden.

Epidemiology

Global Burden of TB and Diabetes

Tuberculosis (TB) remains one of the top ten causes of death worldwide, particularly in low- and middle-income countries. The World Health Organization (WHO) reported approximately 10 million new TB cases in 2020, with an estimated 1.5 million deaths [4]. TB is predominantly a disease of poverty, with the highest burden in regions like sub-Saharan Africa, Southeast Asia, and the Western Pacific. Meanwhile, diabetes mellitus (DM) is a rapidly growing global health concern. In 2021, the International Diabetes Federation (IDF) estimated that 537 million adults were living with diabetes, a number expected to rise to 643 million by 2030 [5]. The prevalence of diabetes is particularly high in countries with significant TB burdens, creating a dangerous interplay between these two conditions. The co-prevalence of TB and diabetes is increasing, with diabetes being recognized as a significant risk factor for TB. Studies have shown that diabetic patients have approximately three times the risk of developing TB compared to non-diabetic individuals. This increased susceptibility is due to the compromised immune system associated with chronic hyperglycemia, which impairs the body's ability to combat infections like TB. The convergence of these diseases is particularly concerning in areas with high diabetes growth rates and existing TB burdens, such as India, China, Indonesia, and Brazil [6].

Risk Factors for Co-occurrence

The risk factors contributing to the co-occurrence of TB and diabetes are multifaceted, involving both biological and socio-environmental components. Shared risk factors include poverty, malnutrition, urbanization, smoking, alcohol use, and exposure to environmental pollutants. These factors are compounded by the challenges of healthcare access and systemic weaknesses

in many regions heavily burdened by TB and diabetes [7].

Age and Gender: Both TB and diabetes prevalence increase with age. Older adults are at a higher risk due to weakened immunity, a longer exposure time to TB, and a higher likelihood of developing type 2 diabetes. Gender differences also play a role, with males often showing higher TB incidence rates, while diabetes is more evenly distributed or slightly higher among females in some populations [8].

Socioeconomic Factors: Poverty, low education levels, and limited access to healthcare significantly increase the risk of both TB and diabetes. Individuals in lower socioeconomic brackets may have inadequate access to nutritious food, healthcare, and TB preventive measures, compounding their risk of co-infection [9].

HIV Co-infection: TB and HIV are a well-documented deadly combination, and diabetes further complicates this triad. HIV patients with diabetes are at a particularly high risk of TB due to the compounded immunosuppressive effects of both HIV and diabetes, which significantly impair the host's ability to mount an effective immune response against TB [10].

Pathophysiology

Mechanisms Linking TB and Diabetes

The pathophysiological interplay between TB and diabetes involves complex interactions that heighten susceptibility to active TB in diabetic individuals. Chronic hyperglycemia in diabetes leads to various immune dysfunctions, such as impaired cytokine production, reduced neutrophil activity, and altered macrophage function, all of which are critical components of the body's defense against TB infection [11].

Impaired Immune Response: Diabetic patients exhibit dysfunctional macrophage activity, which is crucial in the initial immune response to Mycobacterium tuberculosis, the causative agent of TB. This dysfunction includes reduced phagocytosis, impaired formation of reactive oxygen species, and decreased antigen presentation. Additionally, lymphocytes in diabetic patients show reduced proliferation and cytokine production, compromising the host's ability to control TB infection effectively [12].

Hyperglycemia-Induced Inflammation: Chronic hyperglycemia leads to a state of systemic inflammation characterized by elevated levels of pro-inflammatory cytokines like IL-6 and TNF- α . This inflammatory milieu can exacerbate TB infection, as excessive

inflammation can damage host tissues and compromise the immune response further. Hyperglycemia also affects the integrity of the pulmonary alveolar epithelium, increasing the susceptibility to respiratory infections, including TB [13].

Altered Metabolism and Immune Dysfunction: Diabetes is associated with insulin resistance and altered metabolism, which can further impair immune function. Insulin resistance has been linked to altered macrophage metabolism, skewing these immune cells towards a pro-inflammatory state that is less effective in controlling TB. The impaired immune response and systemic inflammation in diabetes create an environment conducive to the reactivation of latent TB infection or progression from infection to active disease [14].

Bidirectional Effects

The relationship between TB and diabetes is bidirectional, with each disease adversely affecting the course of the other. TB can worsen glycemic control in diabetic patients, complicating diabetes management and potentially leading to poor outcomes [15].

Impact of TB on Glycemic Control: TB infection can exacerbate hyperglycemia through various mechanisms, including increased production of stress hormones like cortisol and catecholamines, which promote gluconeogenesis and insulin resistance. Additionally, the systemic inflammatory response to TB can lead to insulin resistance and altered glucose metabolism, making glycemic control more challenging [16].

Influence of Antitubercular Treatment on Glucose Metabolism: Antitubercular drugs, particularly rifampicin, can interfere with glucose metabolism. Rifampicin induces hepatic enzymes that increase the clearance of oral hypoglycemic agents, potentially leading to poor glycemic control. Other drugs used in TB treatment, such as isoniazid and pyrazinamide, can also affect insulin secretion and glucose metabolism, complicating diabetes management [17].

Clinical Manifestations

Symptoms and Presentation

The clinical presentation of TB in diabetic patients can be atypical and often more severe compared to non-diabetic individuals. This atypical presentation may delay diagnosis and worsen outcomes [10].

Pulmonary Manifestations: Diabetic patients with TB are more likely to present with atypical pulmonary features, such as lower lobe involvement, bilateral disease, and cavitary lesions that are more extensive and may persist longer despite treatment. These atypical

radiological findings can lead to diagnostic challenges and delayed treatment initiation [18].

Extrapulmonary TB: Diabetes increases the risk of extrapulmonary TB, including forms like lymphadenitis, pleural effusion, and disseminated TB. The risk of TB meningitis is also elevated, posing a significant threat due to its high mortality rate and potential for neurological sequelae [19].

Systemic Symptoms: Systemic symptoms such as fever, night sweats, weight loss, and fatigue are common in TB but may be less pronounced or masked by symptoms of poorly controlled diabetes, such as polyuria, polydipsia, and unintentional weight loss, complicating the clinical picture [20].

Complications

Complications from the co-occurrence of TB and diabetes include higher rates of treatment failure, relapse, and drug resistance. The dual burden of TB and diabetes also increases the risk of cardiovascular complications, kidney disease, and other diabetes-related comorbidities, further complicating the clinical management of these patients [21].

Increased Risk of Drug Resistance: Diabetic patients with TB have an increased risk of developing multidrug-resistant TB (MDR-TB), likely due to poor glycemic control affecting drug absorption and metabolism, suboptimal adherence to lengthy TB treatment regimens, and possible drug-drug interactions [22].

Delayed Sputum Conversion: Diabetic patients often show delayed sputum culture conversion compared to non-diabetic TB patients, leading to prolonged infectious periods, increased transmission risk, and worse outcomes. This delay is linked to impaired immune function and the severity of disease at presentation [23].

Mortality and Morbidity: The mortality rate for TB among diabetic patients is higher than in those without diabetes. This increased mortality is attributed to delayed diagnosis, more severe disease, complications from poor glycemic control, and comorbid conditions common in diabetes patients [24].

Diagnosis

Challenges in Diagnosis

Diagnosing TB in diabetic patients presents unique challenges. The overlap of symptoms, such as weight loss and fatigue, can obscure clinical suspicion of TB in diabetic individuals. Additionally, atypical radiological findings in diabetic patients can complicate the interpretation of chest X-rays, leading to delays in diagnosis [25].

Limitations of Conventional Diagnostics: The sensitivity of conventional diagnostic methods, such as sputum smear microscopy, may be reduced in diabetic patients, particularly those with atypical pulmonary involvement or extrapulmonary disease. Culture methods, while more sensitive, are time-consuming and may not be readily available in resource-limited settings.

Role of Newer Diagnostic Modalities: Molecular diagnostic tools, such as nucleic acid amplification tests (NAATs) and interferon-gamma release assays (IGRAs), offer more rapid and accurate detection of TB, including in diabetic patients. These tests can help overcome some limitations of traditional diagnostics, although their availability and cost may be limiting factors in low-resource settings.

Screening and Monitoring

Routine screening for TB in diabetic patients, and vice versa, is recommended in high-burden settings. Early detection of TB in diabetic patients can significantly reduce morbidity and mortality. Monitoring for TB should include regular assessment of symptoms, chest radiographs, and TB skin tests or IGRA, especially in regions with high TB prevalence.

Screening Guidelines: The WHO and other public health bodies recommend integrated screening programs that target high-risk groups, including diabetic patients, for TB testing. Similarly, screening for diabetes should be considered in patients diagnosed with TB, given the bidirectional impact of these conditions.

Treatment and Management

TB Treatment in Diabetic Patients

The standard treatment regimen for drug-susceptible TB includes a combination of four first-line antitubercular drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide. This regimen is typically administered for six months, with the initial two months comprising the intensive phase, followed by a four-month continuation phase. While this regimen is effective for most TB patients, diabetic patients present unique challenges that necessitate careful management [26].

Drug-Drug Interactions: One of the main challenges in treating TB in diabetic patients is the potential for drug-drug interactions between antitubercular medications and diabetes medications. For example, rifampicin, a key component of TB treatment, is a potent inducer of hepatic cytochrome P450 enzymes, which can lead to increased metabolism and decreased efficacy of certain oral hypoglycemic agents, such as sulfonylureas. This interaction necessitates closer monitoring of blood

glucose levels and potential adjustments in diabetes medication dosages.

Glycemic Control During TB Treatment: Poor glycemic control can worsen TB outcomes, leading to prolonged disease duration, higher relapse rates, and increased mortality. Effective management of diabetes during TB treatment is critical and should include frequent monitoring of blood glucose levels, individualized nutritional support, and adjustments in diabetes medication regimens to account for changes in metabolism due to TB and its treatment.

Adherence to Treatment: Adherence to the full course of TB treatment is crucial for curing the disease and preventing drug resistance. However, diabetic patients may struggle with treatment adherence due to the complexity of managing both conditions, side effects from multiple medications, and potential socio-economic barriers. Health care providers should employ strategies such as directly observed therapy (DOT), patient education, and support systems to improve adherence in this population.

Diabetes Management During TB Treatment

Adjustments in Diabetes Medications: As previously mentioned, rifampicin can alter the metabolism of certain diabetes medications, necessitating dose adjustments or changes in medication type. Insulin therapy may be preferred during TB treatment due to its rapid and adjustable dosing, which can provide better glycemic control in the face of fluctuating blood glucose levels due to infection and inflammation.

Monitoring for Complications: Diabetic patients undergoing TB treatment should be closely monitored for potential complications such as lactic acidosis, particularly when using metformin, and for liver function abnormalities, as both TB medications and diabetes can impact liver health. Regular liver function tests, kidney function tests, and monitoring for signs of peripheral neuropathy are recommended.

Nutritional Support: Nutrition plays a vital role in the management of both TB and diabetes. Diabetic patients with TB often experience significant weight loss and nutritional deficiencies due to the catabolic effects of TB. A balanced diet rich in protein, vitamins, and minerals can support immune function and improve both TB and diabetes outcomes. Nutrition counseling should be an integral part of the management plan, with tailored recommendations based on the patient's nutritional status, dietary preferences, and glycemic goals.

Addressing Multidrug-Resistant TB

Multidrug-resistant TB (MDR-TB) poses a significant challenge in diabetic patients due to the complexity of treatment, which involves second-line drugs that are often less effective, more toxic, and require longer treatment durations. Diabetic patients are at higher risk of developing MDR-TB due to factors like delayed diagnosis, suboptimal glycemic control, and potential for drug interactions affecting TB drug efficacy [27].

Treatment Regimens: MDR-TB treatment typically involves a combination of second-line drugs, such as fluoroquinolones and injectable agents (e.g., amikacin, capreomycin), along with newer drugs like bedaquiline and delamanid. These regimens are generally longer, lasting 18-24 months, and come with a higher risk of adverse effects, including nephrotoxicity, ototoxicity, and QT prolongation. Careful monitoring and supportive care are essential to manage these side effects and improve treatment outcomes in diabetic patients with MDR-TB.

Individualized Treatment Plans: Due to the complexity of managing MDR-TB in the presence of diabetes, individualized treatment plans are essential. These plans should consider the patient's overall health status, drug resistance profile, and potential drug interactions. Close coordination between TB specialists, endocrinologists, and other healthcare providers is crucial to optimize treatment and address the challenges of co-management.

Prevention Strategies

Preventing TB in Diabetic Patients

Given the increased susceptibility of diabetic patients to TB, preventive measures are critical to reducing the incidence of TB in this population. Prevention strategies include both clinical and public health approaches, such as vaccination, preventive therapy, and lifestyle modifications [28].

Vaccination: The *Bacille Calmette-Guérin (BCG)* vaccine, while primarily used in newborns, offers some protection against severe forms of TB, such as TB meningitis in children. However, its efficacy in preventing pulmonary TB in adults is variable and generally considered limited. Efforts are ongoing to develop more effective TB vaccines that could provide better protection for high-risk groups, including diabetic patients.

Latent TB Infection (LTBI) Screening and Treatment: Screening for latent TB infection in diabetic patients, particularly those living in high TB burden areas, can help identify those at risk of progressing to active TB.

The use of IGRAs or tuberculin skin tests (TST) can aid in diagnosing LTBI. Treatment of LTBI with isoniazid, rifampicin, or a combination regimen can significantly reduce the risk of developing active TB, although careful monitoring is required to manage potential drug interactions and side effects.

Lifestyle Modifications: Lifestyle factors such as smoking, alcohol use, and poor nutrition can exacerbate the risk of TB in diabetic patients. Smoking cessation programs, alcohol reduction strategies, and nutritional counseling should be integral components of TB prevention strategies in diabetic populations.

Preventing Diabetes in TB Patients

Prevention of diabetes in TB patients is equally important, as the onset of diabetes can complicate TB management and worsen outcomes. Preventive strategies include promoting healthy lifestyles, early detection of prediabetes, and implementing interventions to halt the progression to diabetes [29].

Screening for Diabetes in TB Patients: Routine screening for diabetes in TB patients should be standard practice, especially in regions with high prevalence rates of both diseases. Screening can be done using fasting blood glucose tests, HbA1c measurements, or oral glucose tolerance tests. Early detection of impaired glucose tolerance or prediabetes allows for timely interventions that can prevent progression to full-blown diabetes.

Lifestyle Interventions: Educating TB patients on the importance of a healthy diet, regular physical activity, and maintaining a healthy weight can help reduce the risk of developing diabetes. These lifestyle interventions not only support overall health but can also improve TB treatment outcomes by enhancing immune function and reducing inflammation.

Pharmacologic Interventions: In patients with prediabetes or those at high risk of developing diabetes, pharmacologic interventions such as metformin may be considered to prevent the progression to diabetes. Metformin has been shown to improve insulin sensitivity and has potential benefits in reducing TB-associated hyperglycemia, although careful monitoring for lactic acidosis is needed.

Public Health Implications and Strategies

Integrated Care Models

Addressing the dual burden of TB and diabetes requires integrated care models that bring together TB and diabetes services under a unified approach. This integrated care should be patient-centered, with a focus

on coordinated management, shared decision-making, and addressing the social determinants of health [30].

Coordinated Screening and Treatment: Integrated care models should include coordinated screening for TB in diabetic patients and vice versa, as well as streamlined referral pathways to ensure timely and effective treatment. Health systems should aim to provide comprehensive care that includes both TB and diabetes management, with trained healthcare providers capable of addressing the complexities of co-infection.

Training and Capacity Building: Strengthening healthcare provider capacity through training on the management of TB-diabetes comorbidity is essential. Training programs should focus on the latest evidence-based guidelines, practical skills for managing complex cases, and strategies for improving patient adherence to treatment regimens.

Policy and Funding

Policy Development: National health policies should prioritize the co-management of TB and diabetes, with guidelines that emphasize the integration of services and the need for targeted screening and prevention efforts. Policymakers should consider the development of national action plans that address the dual burden of TB and diabetes, with specific goals and metrics for monitoring progress.

Funding and Resources: Adequate funding is critical to support the integrated management of TB and diabetes. Resources should be allocated for infrastructure improvements, procurement of diagnostic tools, training of healthcare workers, and patient support programs. Investment in research to understand the epidemiology, pathophysiology, and best practices for managing TB-diabetes comorbidity is also essential.

Public Awareness and Education

Public awareness campaigns are vital for educating communities about the link between TB and diabetes and the importance of early diagnosis and treatment adherence. These campaigns should target high-risk populations and use culturally appropriate messaging to promote health-seeking behaviors and reduce stigma associated with both TB and diabetes.

Community Engagement: Engaging communities in the fight against TB and diabetes is crucial for success. Community health workers, patient advocacy groups, and local leaders can play a pivotal role in raising awareness, providing education, and supporting patients through their treatment journeys. Efforts should also focus on addressing social determinants of health, such

as poverty, food insecurity, and access to healthcare, which significantly impact the risk and outcomes of both diseases.

Conclusion

The intersection of TB and diabetes represents a significant public health challenge that requires urgent attention and a coordinated response. The bidirectional relationship between these two diseases exacerbates their impact, leading to higher morbidity and mortality, especially in resource-limited settings. Effective management of TB-diabetes comorbidity requires an integrated approach that includes early diagnosis, synchronized treatment protocols, and enhanced patient education. Strengthening healthcare systems, fostering interdisciplinary collaboration, and investing in research are crucial steps to mitigate the burden of this dual epidemic and improve patient outcomes.

Authors' contributions

ICMJE criteria	Details	Author(s)
1. Substantial contributions	Conception, OR Design of the work, OR Data acquisition, analysis, or interpretation	1,2 1,2,3 4,5
2. Drafting or reviewing	Draft the work, OR Review critically for important intellectual content	1,2,3 4,5
3. Final approval	Approve the version to be published	1,2,3,4,5
4. Accountable	Agree to be accountable for all aspects of the work	1,2,3,4,5

Acknowledgement

None

Funding

This research study received no specific grant from any funding agency.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

References

- [1]. Krishna S, Jacob JJ. Diabetes mellitus and tuberculosis. Endnote text Available from: [https://www.ncbi.nlm.nih.gov/books/NBK570126/]. 2021.
- [2]. Hayashi S, Chandramohan D. Risk of active tuberculosis among people with diabetes mellitus: Systematic review and meta-analysis. *Trop Med Int Health*. 2018;23(10):1058-70.
- [3]. Pinto CM, Carvalho AR. Diabetes mellitus and tb co-existence: Clinical implications from a fractional order modelling. *Applied Mathematical Modelling*. 2019;68(4):219-43.
- [4]. Organization WH. Global tuberculosis report 2021: Supplementary material: World Health Organization; 2022.
- [5]. Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A. Prevalence of diabetes in india: A review of idf diabetes atlas 10th edition. *Cur Diab Rev*. 2024;20(1):105-14.
- [6]. Lee P-H, Fu H, Lee M, Magee M, Lin H. Tuberculosis and diabetes in low and moderate tuberculosis incidence countries. *Int J Tuberc Lung Dis*. 2018;22(1):7-16.
- [7]. Alemu A, Bitew ZW, Diriba G, Gumi B. Co-occurrence of tuberculosis and diabetes mellitus, and associated risk factors, in ethiopia: A systematic review and meta-analysis. *Int J Infect Dis Regions*. 2021;1(1):82-91.
- [8]. Ijioma C, Omole O, Orji O, Aminu-Ayinde O, Kalesanwo E, Okeji I, et al. Co-morbidity of chronic and communicable diseases in nigeria: A study on the relationship between diabetes and tuberculosis. *EC Pulmonol Resp Med*. 2023;12(5):01-17.
- [9]. Jarde A, Romano E, Afaq S, Elsony A, Lin Y, Huque R, et al. Prevalence and risks of tuberculosis multimorbidity in low-income and middle-income countries: A meta-review. *BMJ Open*. 2022;12(9):e060906.
- [10]. Goletti D, Pisapia R, Fusco F, Aiello A, Van Crevel R. Epidemiology, pathogenesis, clinical presentation and management of tb in patients with hiv and diabetes. *Int J Tuberc Lung Dis*. 2023;27(4):284-90.
- [11]. Ngo MD, Bartlett S, Ronacher K. Diabetes-associated susceptibility to tuberculosis: Contribution of hyperglycemia vs. Dyslipidemia. *Microorganisms*. 2021;9(11):2282.
- [12]. Ferlita S, Yegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 diabetes mellitus and altered immune system leading to susceptibility to pathogens, especially mycobacterium tuberculosis. *J Clin Med*. 2019;8(12):2219.
- [13]. Krishna S, Jacob JJ. Diabetes mellitus and tuberculosis. *Eur PMC*. 2021;44:712-845.
- [14]. Kumar R, Singh P, Kolloli A, Shi L, Bushkin Y, Tyagi S, et al. Immunometabolism of phagocytes during mycobacterium tuberculosis infection. *Front Mol Biosci*. 2019;6(10):105.
- [15]. Jiang Y, Zhang W, Wei M, Yin D, Tang Y, Jia W, et al. Associations between type 1 diabetes and pulmonary tuberculosis: A bidirectional mendelian randomization study. *Diabetol Metabol Syndr*. 2024;16(1):60.
- [16]. Zhao L, Gao F, Zheng C, Sun X. The impact of optimal glycemic control on tuberculosis treatment outcomes in patients with diabetes mellitus: Systematic review and meta-analysis. *JMIR Public Health Surv*. 2024;10(1):e53948.
- [17]. Sun L, Zhang L, Wang T, Jiao W, Li Q, Yin Q, et al. Mutations of mycobacterium tuberculosis induced by anti-tuberculosis treatment result in metabolism changes and elevation of ethambutol resistance. *Infect Genet Evol*. 2019;72:151-8.
- [18]. Park S, Shin J, Kim J, Park I, Choi B, Choi J, et al. The effect of diabetic control status on the clinical features of pulmonary tuberculosis. *Eu J Clin Microbiol Infect Dis*. 2012;31(10):1305-10.
- [19]. Magee M, Foote M, Ray S, Gandhi N, Kempker R. Diabetes mellitus and extrapulmonary tuberculosis: Site distribution and risk of mortality. *Epidemiol Infect*. 2016;144(10):2209-16.
- [20]. Luies L, Du Preez I. The echo of pulmonary tuberculosis: Mechanisms of clinical symptoms and other disease-induced systemic complications. *Clin Microbiol Rev*. 2020;33(4):10.1128/cmr.00036-20.
- [21]. Shetty S, Pappachan JM, Fernandez CJ. Diabetes and tuberculosis: An emerging dual threat to healthcare. *World J Diab*. 2024;15(7):1409.
- [22]. Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis. *Archivos de Bronconeumología (English Edition)*. 2017;53(5):245-50.
- [23]. Kanda R, Nagao T, Tho NV, Ogawa E, Murakami Y, Osawa M, et al. Factors affecting time to sputum culture conversion in adults with pulmonary tuberculosis: A historical cohort study without censored cases. *PLoS one*. 2015;10(11):e0142607.

- [24]. Ko P-Y, Lin S-D, Hsieh M-C, Chen Y-C. Diabetes mellitus increased all-cause mortality rate among newly-diagnosed tuberculosis patients in an asian population: A nationwide population-based study. *Diab Res Clin Practice*. 2017;133:115-23.
- [25]. Kapur A, Harries AD. The double burden of diabetes and tuberculosis—public health implications. *Diab Res Clin Practice*. 2013;101(1):10-9.
- [26]. Organization WH. Who consolidated guidelines on tuberculosis. Module 4: Treatment-drug-resistant tuberculosis treatment, 2022 update: World Health Organization; 2022.
- [27]. Todoriko L, Crisan-Dabija R, Semianiv I, Shevchenko O, Ostrovskiy M, Yeremenchuk I, et al. Multidrug-resistant tuberculosis and diabetes mellitus as a problem of modern medicine. *Pneumologia*. 2021;70(1):26-33.
- [28]. Koesoemadinata R, McAllister S, Soetedjo N, Santoso P, Dewi N, Permana H, et al. Diabetes characteristics and long-term management needs in diabetic tb patients. *Int J Tuberc lung Dis*. 2023;27(2):113-20.
- [29]. Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lönnroth K, et al. Bi-directional screening for tuberculosis and diabetes: A systematic review. *Trop Med Int Health*. 2010;15(11):1300-14.
- [30]. Harries A, Lin Y, Kumar A, Satyanarayana S, Zachariah R, Dlodlo R. How can integrated care and research assist in achieving the sdg targets for diabetes, tuberculosis and hiv/aids? *Int J Tuberc Lung Dis*. 2018;22(10):1117-26.